# Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

> **NCT04722848** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 236 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
- ALL, Adult
- Philadelphia-Positive ALL

## Interventions

- **DRUG:** Ponatinib + Blinatumomab
- **DRUG:** Chemotherapy + Imatinib

## Key facts

- **NCT ID:** NCT04722848
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-08
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04722848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04722848, "Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04722848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*